About Romark Laboratories

Romark Laboratories (www.romark.com), a privately held biopharmaceutical company, has discovered and developed a new class of small molecule antivirals known as thiazolides. The Company is developing nitazoxanide, the first thiazolide antiviral drug, for the treatment of chronic hepatitis C, and is developing nitazoxanide and other novel thiazolides for treating viral diseases including chronic hepatitis B. Alinia® (nitazoxanide) is approved by the U.S. Food and Drug Administration and marketed by Romark for the treatment of Cryptosporidium parvum and Giardia lamblia infection.